Patent SG-11201810403V-A (SG)
Title: Drug-delivery nanoparticles and treatments for drug-resistant cancer
Inventor: MEDINA -KAUWE LALI
IPC: B82Y5/00
Filed: 2017-05-26
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111111111111111111111111111 010101111001111100111111101111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\"\"1 WO 2017/205764 Al 30 November 2017 (30.11.2017) WIPO I PCT (51) (21) (22) (25) Filing Language: (26) (30) (71) (72) International Patent Classification: (74) Agent: WEINER, Ethan, M. et al.; Morrison & Foerster A61K 45/00 (2006.01) A61P 35/00 (2006.01) LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US). A61K 47/48 (2006.01) B82Y 5/00 (2011.01) (81) Designated States (unless otherwise indicated, for every International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/US2017/034719 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, International Filing Date: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 26 May 2017 (26.05.2017) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, English KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, Publication Language: English MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, Priority Data: SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, 62/342,829 27 May 2016 (27.05.2016) US TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Applicant: CEDARS-SINAI MEDICAL CENTER (84) Designated States (unless otherwise indicated, for every [US/US]; 8700 Beverly Boulevard, Los Angeles, CA 90048 kind of regional protection available): ARIPO (BW, GH, (US). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, Inventor: MEDINA -KAUWE, Lali, K.; 11816 Stewarton TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Drive, Porter Ranch, CA 91326 (US). EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, Title: DRUG-DELIVERY 45 40 35 0 3 E c ,.25 - SI 20 15 10 - 5 0 : Disclosed oligonucleotide, wherein the segment: and composition is less than about 6:1, along with methods of making and using such nanoparticles. Further described are methods of a subject with a cancer, nanoparticles, the and an oligonucleotide-binding segment; a double-stranded oligonucleotide bound to the oligonucleotide-binding segment; a chemotherapeutic drug bound manufacture, and kits comprising the described nanoparticles. (57) cleotide-binding in comprising 0 segment, herein NANOPARTICLES AND TREATMENTS FOR DRUG-RESISTANT CANCER FIG. 2 H: •N\"PBK.1 0 - D NA = (54) = _ - = = — = = — 0 2 to I • 3 to I • 4 to 1 0 5 to 1 ®m'to I 1=IHerPBKIO on • dox nig° .... J. ..„; = = = ....<, \" = --, 4Z' = = — , , = .,-. = = 3 = - = wherein such nanoparticles are compositions comprising nanoparticles comprising a carrier polypeptide and a double-strand- carrier polypeptide comprises a cell-targeting segment, a cell-penetrating segment, and an oligonu- the molar ratio of the carrier polypeptide to the double-stranded oligonucleotide in the nanopar- as a chemotherapeutic drug resistant cancer comprising administering to the subject a composition comprising a carrier polypeptide comprising a cell-targeting segment, a cell-penetrating to the double-stranded oligonucleotide. Also described are pharmaceutical compositions, articles - 7 1 ed 7r tide IN treating ei --.... and IN of 1-1 0 ei O [Continued on next page] WO 2017/205764 Al MIDEDIMOMMIDIRMEM00101011MHINHEMOVOIMIE MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))